AriBio's Oral Alzheimer's Drug Succeeds in Phase 3, Slowing Decline 31% in Monotherapy Group
AI 요약 정보
- AriBio reports 31% slower decline vs placebo in monotherapy
- AR1001 did not significantly beat placebo overall
- AriBio plans further analysis and regulator talks before FDA filing